A REVIEW ON TARGETED DRUG DELIVERY SYSTEMS IN ONCOLOGY

Akshaya G*, Kiran Revadihal, Arindam Dey, Shivani Amireddy, Robin Roy, Shreyaa Datta, Vasudev Purushottam Pai, Sanivarapu Radhika8, Nalajala Akash and R. Roshinee

Targeted Drug Delivery Systems are a milestone in cancer therapy that represents a new level attacking strategy to bring treatment more precise and effective. They aim at delivering therapeutic agents directly to sites established in tumor tissue and avoiding the establishment of systemic toxicity and improving efficacy. Key concepts in TDDS are passive targeting, for example, the enhanced permeability and retention (EPR) effect, and active targeting which employs receptor or biomarker on cancer cells for selective drug delivery. TDDS have also been widely used in chemotherapy, immunotherapy, gene therapy, RNA-based therapies as well as on-cytotoxic drugs, increasing its therapeutic index while reducing side effects. TDDS are increasingly also deployed in multiple therapeutic debtor combinations, where multiple therapeutic agents are delivered collectively. Nanomedicine takes a lead in diagnosis and imaging of cancer to early identification and monitoring of tumor progression. Its role is broadening over time in clinical applications; the rapid increase of TDDS clinical applications gives way to possibly personalized cancer treatment with better outcomes for patients. Nevertheless, barriers still need to be broken so that effective penetration into tumors and controlled release of therapeutic agents can happen. The advances and works in progress in TDDS can ensure the futuristic era of cancer therapy.